Cocrystal Pharma, INC. (COCP) — SEC Filings

Overview

Cocrystal Pharma, INC. (COCP) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Mar 31, 2026: Cocrystal Pharma, Inc. (COCP) is a clinical-stage biotechnology company focused on developing novel antiviral therapeutics for serious viral diseases. For the fiscal year ended December 31, 2025, the company continued its research and development efforts in influenza, norovirus, and coronavirus prog

Sentiment Summary

Across 44 filings, the sentiment breakdown is: 3 bearish, 40 neutral, 1 mixed. The dominant filing sentiment for Cocrystal Pharma, INC. is neutral.

Filing Type Overview

Cocrystal Pharma, INC. (COCP) has filed 3 10-K, 32 8-K, 4 10-Q, 1 S-1, 2 DEF 14A, 1 10-K/A, 1 SC 13G/A with the SEC between Jan 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (44)

• Cocrystal Pharma Faces CRO Dispute Amidst Mixed Clinical Trial Results — 10-K · Mar 31, 2026 Risk: high
  Cocrystal Pharma, Inc. (COCP) is a clinical-stage biotechnology company focused on developing novel antiviral therapeutics for serious viral diseases. For the f
• Cocrystal Pharma Files 8-K — 8-K · Dec 18, 2025 Risk: low
  Cocrystal Pharma, Inc. filed an 8-K on December 18, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, incorporat
• Cocrystal Pharma Files 8-K with Corporate Updates — 8-K · Dec 1, 2025 Risk: low
  Cocrystal Pharma, Inc. filed an 8-K on December 1, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the comp
• Cocrystal Pharma Narrows Q3 Loss Amid R&D Cuts, Liquidity Concerns Persist — 10-Q · Nov 14, 2025 Risk: high
  Cocrystal Pharma, Inc. reported a net loss of $2.049 million for the three months ended September 30, 2025, a significant improvement from the $4.939 million ne
• Cocrystal Pharma Files 8-K: Material Agreement & Equity Sales — 8-K · Oct 30, 2025 Risk: medium
  Cocrystal Pharma, Inc. announced on October 28, 2025, the entry into a material definitive agreement. The company also disclosed unregistered sales of equity se
• Cocrystal Pharma Files 8-K — 8-K · Oct 27, 2025 Risk: low
  Cocrystal Pharma, Inc. filed an 8-K on October 27, 2025, reporting information under Regulation FD and including financial statements and exhibits. The company,
• Cocrystal Pharma Registers 5.7M Shares for Resale; Influenza Study Faces Delays — S-1 · Sep 19, 2025 Risk: high
  Cocrystal Pharma, Inc. (COCP) is a clinical-stage biotechnology company focused on developing novel antiviral therapeutics. The company is not selling any secur
• Cocrystal Pharma Enters Material Agreement, Discloses Equity Sales — 8-K · Sep 15, 2025 Risk: medium
  Cocrystal Pharma, Inc. announced on September 12, 2025, the entry into a material definitive agreement. The company also disclosed unregistered sales of equity
• Cocrystal Pharma Files 8-K — 8-K · Sep 12, 2025 Risk: low
  Cocrystal Pharma, Inc. filed an 8-K on September 12, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not conta
• Cocrystal Pharma Files 8-K on Financials — 8-K · Aug 14, 2025 Risk: low
  Cocrystal Pharma, Inc. filed an 8-K on August 14, 2025, reporting on its results of operations and financial condition. The filing includes financial statements
• Cocrystal Pharma Files 8-K with Corporate Updates — 8-K · Aug 5, 2025 Risk: low
  Cocrystal Pharma, Inc. filed an 8-K on August 5, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the compan
• Cocrystal Pharma Files 8-K — 8-K · Jul 10, 2025 Risk: low
  Cocrystal Pharma, Inc. filed an 8-K on July 10, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, incorporated in D
• Cocrystal Pharma 8-K: Security Holder Vote Matters — 8-K · Jul 1, 2025 Risk: low
  Cocrystal Pharma, Inc. filed an 8-K on June 25, 2025, reporting on matters submitted to a vote of its security holders. The filing details the company's corpora
• Cocrystal Pharma Files 8-K with Bylaw Amendments — 8-K · Jun 18, 2025 Risk: low
  Cocrystal Pharma, Inc. filed an 8-K on June 18, 2025, reporting amendments to its Articles of Incorporation or Bylaws and filing financial statements and exhibi
• Cocrystal Pharma Files 8-K — 8-K · Jun 5, 2025 Risk: low
  Cocrystal Pharma, Inc. filed an 8-K on June 5, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain spe
• Cocrystal Pharma Files 8-K — 8-K · May 29, 2025 Risk: low
  Cocrystal Pharma, Inc. filed an 8-K on May 29, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain spe
• Cocrystal Pharma Files Q1 2025 10-Q — 10-Q · May 15, 2025 Risk: medium
  Cocrystal Pharma, Inc. filed its quarterly report for the period ending March 31, 2025. The company, previously known as BIOZONE PHARMACEUTICALS, INC., is based
• Cocrystal Pharma DEF 14A: Executive Compensation Details — DEF 14A · May 5, 2025 Risk: medium
  Cocrystal Pharma, Inc. filed a DEF 14A on May 5, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes inform
• Cocrystal Pharma Files 8-K with Corporate Updates — 8-K · Apr 24, 2025 Risk: low
  Cocrystal Pharma, Inc. filed an 8-K on April 24, 2025, reporting on Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the compa
• Cocrystal Pharma Files 8-K: Updates and Former Names — 8-K · Apr 23, 2025 Risk: low
  Cocrystal Pharma, Inc. filed an 8-K on April 23, 2025, reporting on Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the compa
• Cocrystal Pharma: Board & Executive Compensation Changes — 8-K · Apr 8, 2025 Risk: medium
  Cocrystal Pharma, Inc. announced on April 2, 2025, a change in its board of directors and executive compensation arrangements. The filing details the departure
• Cocrystal Pharma Files 8-K — 8-K · Apr 1, 2025 Risk: low
  Cocrystal Pharma, Inc. filed an 8-K on April 1, 2025, reporting events as of March 31, 2025. The filing primarily concerns financial statements and exhibits, wi
• Cocrystal Pharma Files 2024 10-K — 10-K · Mar 31, 2025 Risk: medium
  Cocrystal Pharma, Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company, formerly known as BIOZONE PHARMACEUTICALS, INC., is based in Bo
• Cocrystal Pharma Files 8-K — 8-K · Jan 13, 2025 Risk: low
  Cocrystal Pharma, Inc. filed an 8-K on January 13, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not cont
• Cocrystal Pharma Files 8-K — 8-K · Jan 8, 2025 Risk: low
  On January 8, 2025, Cocrystal Pharma, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No
• Cocrystal Pharma Files 8-K with Financials & Reg FD — 8-K · Dec 31, 2024 Risk: low
  Cocrystal Pharma, Inc. filed an 8-K on December 31, 2024, reporting on its financial statements and exhibits. The filing also includes a Regulation FD Disclosur
• Cocrystal Pharma Files 8-K on Financials — 8-K · Nov 13, 2024 Risk: low
  Cocrystal Pharma, Inc. filed an 8-K on November 13, 2024, reporting on its results of operations and financial condition, as well as financial statements and ex
• Cocrystal Pharma Files 8-K — 8-K · Oct 31, 2024 Risk: low
  Cocrystal Pharma, Inc. filed an 8-K on October 31, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain
• Cocrystal Pharma Appoints New Director, Discloses Officer Compensation — 8-K · Oct 10, 2024 Risk: medium
  Cocrystal Pharma, Inc. announced on October 9, 2024, a change in its Board of Directors. Specifically, Dr. David S. Hong has been appointed as a new director, e
• Cocrystal Pharma Files 8-K on Aug 19 Events — 8-K · Aug 20, 2024 Risk: low
  Cocrystal Pharma, Inc. filed an 8-K on August 20, 2024, reporting events as of August 19, 2024. The filing primarily concerns Regulation FD Disclosure and Finan
• Cocrystal Pharma Files Q2 2024 10-Q — 10-Q · Aug 14, 2024 Risk: medium
  Cocrystal Pharma, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business opera
• Cocrystal Pharma Files 8-K — 8-K · Jul 18, 2024 Risk: low
  On July 18, 2024, Cocrystal Pharma, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. No spec
• Cocrystal Pharma Files 8-K on Corporate Changes — 8-K · Jun 28, 2024 Risk: medium
  Cocrystal Pharma, Inc. filed an 8-K on June 28, 2024, reporting on events that occurred on June 25, 2024. The filing indicates changes to its Articles of Incorp
• Cocrystal Pharma Files 8-K — 8-K · Jun 20, 2024 Risk: low
  Cocrystal Pharma, Inc. filed an 8-K on June 20, 2024, reporting information under Regulation FD Disclosure and Financial Statements and Exhibits. The filing det
• Cocrystal Pharma, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 13, 2024 Risk: low
  Cocrystal Pharma, Inc. (COCP) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Cocrystal Pharma, Inc. filed a 10-Q report for the period ending Mar
• Cocrystal Pharma, Inc. Announces 2024 Annual Meeting of Stockholders — DEF 14A · May 7, 2024 Risk: low
  Cocrystal Pharma, Inc. (COCP) filed a Proxy Statement (DEF 14A) with the SEC on May 7, 2024. Annual Meeting scheduled for June 25, 2024, at 11:00 a.m. ET, held
• Cocrystal Pharma Files 8-K — 8-K · May 1, 2024 Risk: low
  Cocrystal Pharma, Inc. filed an 8-K on May 1, 2024, reporting information under Regulation FD Disclosure and Financial Statements and Exhibits. The company, for
• Cocrystal Pharma, Inc. Files Amendment to Annual Report — 10-K/A · Apr 17, 2024 Risk: low
  Cocrystal Pharma, Inc. (COCP) filed a Amended Annual Report (10-K/A) with the SEC on April 17, 2024. Cocrystal Pharma, Inc. filed an amendment (No. 1) to its an
• Cocrystal Pharma, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 28, 2024 Risk: low
  Cocrystal Pharma, Inc. (COCP) filed a Annual Report (10-K) with the SEC on March 28, 2024. Cocrystal Pharma, Inc. filed its 2023 Form 10-K on March 28, 2024. Th
• Cocrystal Pharma Files 8-K — 8-K · Mar 19, 2024 Risk: low
  Cocrystal Pharma, Inc. filed an 8-K on March 19, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contai
• Cocrystal Pharma Terminates Material Agreement — 8-K · Mar 1, 2024 Risk: medium
  Cocrystal Pharma, Inc. announced on February 28, 2024, the termination of a material definitive agreement. The company, incorporated in Delaware, filed this 8-K
• Cocrystal Pharma Confirms Nasdaq Listing Under COCP — 8-K · Jan 8, 2024
  Cocrystal Pharma, Inc. filed an 8-K on January 8, 2024, primarily to disclose its registration on The Nasdaq Stock Market LLC under the trading symbol COCP. Thi
• Cocrystal Pharma 8-K: General Corporate Info, Nasdaq Listing Confirmed — 8-K · Jan 4, 2024
  Cocrystal Pharma, Inc. filed an 8-K on January 4, 2024, primarily to disclose general corporate information and confirm its common stock, trading under the symb
• Sabby Volatility Exits Cocrystal Pharma Position — SC 13G/A · Jan 2, 2024
  Sabby Volatility Warrant Master Fund, Ltd. filed an amended SC 13G/A for Cocrystal Pharma, Inc. on January 2, 2024, indicating they no longer beneficially own a

Risk Profile

Risk Assessment: Of COCP's 41 recent filings, 3 were flagged as high-risk, 10 as medium-risk, and 28 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Cocrystal Pharma, INC.'s most recent 10-K filing (Mar 31, 2026):

• Revenue: $0
• Net Income: N/A
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: N/A
• Operating Margin: N/A
• Total Assets: N/A
• Total Debt: N/A

Key Executives

• Dr. Roger Kornberg
• James Martin
• Michael D. Harris, Esq.
• Roger Kornberg
• Sam Lee
• Dr. David S. Hong

Industry Context

Cocrystal Pharma operates in the highly competitive biotechnology sector, focusing on antiviral therapeutics. The company faces significant challenges from established pharmaceutical companies and other emerging biotechs developing treatments for widespread viral diseases like influenza and COVID-19. The industry is characterized by long development cycles, high R&D costs, and stringent regulatory hurdles, with a constant need for innovation to address evolving viral strains and unmet medical needs.

Top Tags

disclosure (8) · 8-K (7) · corporate-governance (7) · financials (6) · regulatory-filing (6) · 8-k (5) · corporate-disclosure (4) · filing (4) · sec-filing (4) · Biotechnology (3)

Key Numbers

• CRO payment dispute: $6.3M — refund requested for failed CC-42344 Phase 2a study
• Market Value (Non-Affiliate Equity): $11.6M — as of June 30, 2025, indicating small market capitalization
• Shares Outstanding: 13,785,759 — as of March 24, 2026
• CDI-988 High Dose: 1200 mg — evaluated in Phase 1 study with favorable safety
• COVID-19 Reported Cases: 777 million — globally as of February 2026
• COVID-19 Deaths: 7 million — globally as of February 2026
• Seasonal Influenza Cases: 1 billion — worldwide annually, according to WHO
• Seasonal Influenza Deaths: 650,000 — worldwide annually, according to WHO
• US Population Influenza Rate: 8% — contracts influenza each season, according to CDC
• US Annual Influenza Medical Costs: $10.4 billion — according to NIH
• Net Loss (9 months): $6.405M — Decreased from $14.238M in 2024, indicating improved financial performance but still a loss.
• R&D Expenses (9 months): $3.436M — Significantly reduced from $10.500M in 2024, impacting future product pipeline.
• Cash & Restricted Cash: $7.804M — As of September 30, 2025, down from $9.935M at year-end 2024, highlighting liquidity concerns.
• Cash Used in Operations (9 months): $6.456M — Indicates continued cash burn, contributing to the 'going concern' doubt.
• Financing Proceeds (9 months): $4.337M — Raised through stock sales, crucial for current operations but dilutive.

Related Companies

CCPH

Frequently Asked Questions